China has the world's largest burden of hepatitis B virus (HBV) infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. One of the main issues in the management of patients with chronic HBV infection (CHB) is to maximize the individuals who need the treatment engaged and retained in care. However, our investigation revealed that 21.1% patients were treatment eligible but not treated based on Chinese 2019 CHB treatment guidelines, while only 213 (13.9%) patients were indicated-but-not-treated according to AASLD 2018 Hepatitis B guidance in a real-life cohort study. To maximize the individuals who need the treatment engaged and retained in care, integrated intervention strategies to address these treatment barriers are urgently needed. Therefore, we aim to propose a study to narrow the gap between in accordance with guidelines and consent to treat CHB population in EAST of China.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
2,000
Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
The Third People's Hospital of Changzhou
Changzhou, Jiangsu, China
Huai'an No.4 People's Hospital
Huai'an, Jiangsu, China
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
The Affiliated Infectious Diseases Hospital of Soochow University
Suzhou, Jiangsu, China
The proportion of indicated-but-not-treated CHB patients.
The proportion of indicated-but-not-treated CHB patients.
Time frame: 18 months
The proportion of lost to follow-up in CHB patients.
Time frame: 18 months
The frequency of follow-up visit in CHB patients.
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.